Reaction
Myelofibrosis reporting signals
As of the last recalculation, Myelofibrosis appears in 2,989 FAERS reports alongside 34 co-occurring drug terms. The strongest observed disproportionality signal is RUXOLITINIB (PRR 130.9).
Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.
| Drug | Co-reports | PRR | ROR |
|---|---|---|---|
| Ruxolitinib | 931 | 130.9 | 132.7 |
| Hydroxyurea | 269 | 97.2 | 98.5 |
| Romiplostim | 156 | 76.1 | 76.9 |
| Eltrombopag Olamine | 107 | 33.5 | 33.6 |
| Deferasirox | 120 | 32.8 | 32.9 |
| Imatinib | 46 | 18.4 | 18.5 |
| Azacitidine | 72 | 17.3 | 17.3 |
| Thalidomide | 74 | 14.4 | 14.4 |
| Azacitidine For | 30 | 11.6 | 11.6 |
| Erythropoietin | 27 | 9.2 | 9.2 |
| Nilotinib | 32 | 7.6 | 7.6 |
| Busulfan | 17 | 7.6 | 7.6 |
| Allopurinol | 150 | 7.0 | 7.0 |
| Febuxostat Tablets 40 Mg | 10 | 6.9 | 6.9 |
| Febuxostat Tablets 80 Mg | 10 | 6.9 | 6.9 |
| Dalteparin Sodium | 10 | 6.6 | 6.6 |
| Epoetin Alfa | 11 | 6.5 | 6.5 |
| Imatinib Mesylate | 24 | 6.0 | 6.0 |
| Febuxostat | 13 | 5.4 | 5.4 |
| Sirolimus | 10 | 5.2 | 5.2 |
| Cytarabine | 41 | 4.8 | 4.8 |
| Ticagrelor | 17 | 3.7 | 3.7 |
| Avapritinib | 6 | 3.5 | 3.5 |
| Ifosfamide | 10 | 3.2 | 3.2 |
| Vismodegib | 4 | 3.1 | 3.1 |
| Darbepoetin Alfa | 23 | 3.0 | 3.0 |
| Venetoclax | 26 | 3.0 | 3.0 |
| Acalabrutinib | 5 | 2.9 | 2.9 |
| Dofetilide | 4 | 2.7 | 2.7 |
| Dasatinib | 14 | 2.6 | 2.6 |
| Obinutuzumab | 6 | 2.5 | 2.5 |
| Bosutinib | 3 | 2.3 | 2.3 |
| Peginterferon Alfa-2A | 17 | 2.2 | 2.2 |
| Lenalidomide | 88 | 1.5 | 1.5 |